FOR ADULTS WITH TYPE 2 DIABETES, ALONG WITH DIET AND EXERCISE

Frequently asked questions

Included here are answers to some of the most frequently asked questions about TRIJARDY XR. More detailed information can be found by following the links.

TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin XR in 1 pill, and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

TRIJARDY XR is not recommended in patients with type 1 diabetes. It may increase the risk of diabetic ketoacidosis in these patients. TRIJARDY XR has not been studied in patients with a history of pancreatitis, and it is unknown if using TRIJARDY XR increases the risk of developing pancreatitis in these patients.

Find out more

TRIJARDY XR is an antiglycemic therapy that contains 3 different medications (empagliflozin, linagliptin, and metformin XR) in 1 pill as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

TRIJARDY XR is not recommended in patients with type 1 diabetes. It may increase the risk of diabetic ketoacidosis in these patients. TRIJARDY XR has not been studied in patients with a history of pancreatitis, and it is unknown if using TRIJARDY XR increases the risk of developing pancreatitis in these patients.

Find out more

In a clinical trial, the components of TRIJARDY XR were shown to significantly reduce A1C levels in adult patients with type 2 diabetes when administered together, compared to the components administered individually.

Find out more

There are 2 main dosing options for TRIJARDY XR: a single pill to be taken once a day or 2 pills to be taken once a day.

Find out more

TRIJARDY XR is covered by many private insurance and Medicare Part D plans.

Find out more

Eligible patients* may pay as little as $10 a month for a 1- to 3-month prescription—card can continue to be used to save on refills as long as patient still qualifies.

*TRIJARDY XR Savings Card Terms & Conditions apply. Medicare/Medicaid/cash-paying patients excluded from Savings Card enrollment.

Find out more

TRIJARDY XR: 3 ways to reduce A1C

Each component of TRIJARDY XR has a distinct mechanism of action:

Jardiance® (empagliflozin) is an SGLT2 inhibitor, which reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion
TRADJENTA® (linagliptin) is a DPP-4 inhibitor, which increases the concentrations of active incretin hormones (GLP-1 and GIP), thus stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation
Metformin XR is an antihyperglycemic agent, which decreases glucose production in the liver, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization

The 3 constituents of TRIJARDY XR go further to reduce A1C

DPP-4=dipeptidyl peptidase-4; SGLT2=sodium glucose co-transporter-2.

See pill size comparison

IMPORTANT SAFETY INFORMATION

WARNING: LACTIC ACIDOSIS WITH TRIJARDY XR

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL.

Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the full Prescribing Information.

If lactic acidosis is suspected, discontinue TRIJARDY XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.

INDICATIONS AND LIMITATIONS OF USE FOR JARDIANCE, TRADJENTA and TRIJARDY XR

JARDIANCE is indicated to reduce the risk of cardiovascular (CV) death plus hospitalization for heart failure in adults with heart failure and reduced ejection fraction; and reduce the risk of CV death in adults with type 2 diabetes mellitus and established CV disease.

JARDIANCE, TRADJENTA and TRIJARDY XR are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use

TRADJENTA is not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

JARDIANCE and TRIJARDY XR are not recommended in patients with type 1 diabetes mellitus. It may increase their risk of diabetic ketoacidosis.

TRADJENTA and TRIJARDY XR have not been studied in patients with a history of pancreatitis, and it is unknown if using TRADJENTA or TRIJARDY XR increases the risk of developing pancreatitis in these patients.

JARDIANCE is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR <30 mL/min/1.73 m2. JARDIANCE is likely to be ineffective in this setting based upon its mechanism of action.

CONTRAINDICATIONS

JARDIANCE: Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE, reactions such as angioedema have occurred; patients on dialysis.

TRADJENTA: Hypersensitivity to linagliptin, or any of the excipients in TRADJENTA, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.

TRIJARDY XR: Severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease, or dialysis; acute or chronic metabolic acidosis, including diabetic ketoacidosis; hypersensitivity to empagliflozin, linagliptin, metformin, or any of the excipients in TRIJARDY XR, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.

WARNINGS AND PRECAUTIONS

Lactic Acidosis: TRIJARDY XR

There have been cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypothermia, hypotension, and resistant bradyarrhythmias have occurred with severe acidosis. Additional findings included elevated blood lactate concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio, metformin plasma levels generally >5 mcg/mL.

If lactic acidosis is suspected, immediately discontinue TRIJARDY XR and institute general supportive measures promptly in a hospital setting. Prompt hemodialysis is recommended to correct the acidosis.

Educate patients and their families about the symptoms of lactic acidosis and, if these symptoms occur, instruct them to discontinue TRIJARDY XR and promptly notify their healthcare provider.

Recommendations to reduce the risk include:

  • Renal Impairment: Obtain eGFR prior to initiating and annually or more frequently in patients at increased risk of developing renal impairment.
  • Drug Interactions: More frequent monitoring is recommended when administered with drugs that impair renal function, result in hemodynamic change, interfere with acid-base balance, or increase metformin accumulation.
  • Age 65 or Greater: Assess renal function more frequently.
  • Radiological Studies with Contrast: Stop TRIJARDY XR at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR of <60 mL/min/1.73m2; patients with a history of hepatic impairment, alcoholism or heart failure; or patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the procedure and restart TRIJARDY XR if renal function is stable.
  • Surgery and Other Procedures: Discontinue while patients have restricted food and fluid intake.
  • Hypoxic States: Discontinue in conditions associated with hypoxemia.
  • Excessive Alcohol Intake: Warn patients against excessive alcohol intake.
  • Hepatic Impairment: Avoid use in patients with hepatic disease.

Pancreatitis: TRADJENTA, TRIJARDY XR

Acute pancreatitis, including fatal pancreatitis, has been reported in patients taking linagliptin, a component of TRADJENTA or TRIJARDY XR. Take careful notice of potential signs and symptoms of pancreatitis and, if suspected, promptly discontinue and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using TRADJENTA or TRIJARDY XR.

Heart Failure: TRADJENTA, TRIJARDY XR

Heart failure has been observed with two other members of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Consider risks and benefits of TRADJENTA or TRIJARDY XR in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment. Monitor patients for signs and symptoms. Advise patients of the symptoms of heart failure and to immediately report such symptoms. If heart failure develops, consider discontinuation of TRADJENTA or TRIJARDY XR.

Ketoacidosis: JARDIANCE, TRIJARDY XR

Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been identified in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose co-transporter-2 (SGLT2) inhibitors, including empagliflozin. Fatal cases of ketoacidosis have been reported in patients taking empagliflozin. Patients who present with signs and symptoms of metabolic acidosis should be assessed for ketoacidosis, even if blood glucose levels are less than 250 mg/dL. If suspected, discontinue, evaluate, and treat promptly. Before initiating, consider risk factors for ketoacidosis. Patients may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis. For patients who undergo scheduled surgery, consider temporarily discontinuing for at least 3 days prior to surgery.

Volume Depletion: JARDIANCE, TRIJARDY XR

Empagliflozin can cause intravascular volume depletion which may manifest as symptomatic hypotension or acute transient changes in creatinine. Acute kidney injury requiring hospitalization and dialysis has been reported in patients with type 2 diabetes receiving SGLT2 inhibitors, including empagliflozin. Before initiating, assess volume status and renal function in patients with impaired renal function (eGFR<60 mL/min/1.73 m2), elderly patients or patients on loop diuretics. After initiating, monitor for signs and symptoms of hypotension, and renal function.

Urosepsis and Pyelonephritis: JARDIANCE, TRIJARDY XR

Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have been identified in patients receiving SGLT2 inhibitors, including empagliflozin. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate for signs and symptoms of urinary tract infections and treat promptly.

Hypoglycemia: JARDIANCE, TRADJENTA, TRIJARDY XR

The use in combination with insulin or insulin secretagogues can increase the risk of hypoglycemia. A lower dose of insulin or the insulin secretagogue may be required.

Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): JARDIANCE, TRIJARDY XR

Serious, life-threatening cases requiring urgent surgical intervention have occurred in both females and males. Serious outcomes have included hospitalization, multiple surgeries and death. Assess patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise. If suspected, institute prompt treatment and discontinue JARDIANCE or TRIJARDY XR.

Genital Mycotic Infections: JARDIANCE, TRIJARDY XR

Empagliflozin increases the risk for genital mycotic infections, especially in patients with prior infections. Monitor and treat as appropriate.

Hypersensitivity Reactions

JARDIANCE: Serious hypersensitivity reactions have occurred with empagliflozin (angioedema). If hypersensitivity reactions occur, discontinue JARDIANCE, treat promptly, and monitor until signs and symptoms resolve.

TRADJENTA, TRIJARDY XR: Serious hypersensitivity reactions have occurred with linagliptin (anaphylaxis, angioedema and exfoliative skin conditions) and empagliflozin (angioedema). If hypersensitivity reactions occur, discontinue TRADJENTA or TRIJARDY XR, treat promptly, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA or TRIJARDY XR.

Vitamin B12 Deficiency: TRIJARDY XR

Metformin may lower vitamin B12 levels. Monitor hematologic parameters annually and vitamin B12 at 2- to 3-year intervals.

Severe and Disabling Arthralgia: TRADJENTA, TRIJARDY XR

Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider linagliptin as a possible cause for severe joint pain and discontinue, if appropriate.

Bullous Pemphigoid: TRADJENTA, TRIJARDY XR

There have been reports of bullous pemphigoid requiring hospitalization. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue.

MOST COMMON ADVERSE REACTIONS (≥5%)

JARDIANCE: urinary tract infections and female genital mycotic infections.

TRADJENTA: nasopharyngitis, hypoglycemia (when used in combination with sulfonylurea).

TRIJARDY XR: upper respiratory tract infections, urinary tract infection, nasopharyngitis, diarrhea, constipation, headache, gastroenteritis.

DRUG INTERACTIONS

JARDIANCE, TRIJARDY XR:

  • Diuretics: Coadministration of empagliflozin with diuretics may enhance the potential for volume depletion. Monitor for signs and symptoms.

TRIJARDY XR:

  • Carbonic Anhydrase Inhibitors: The concomitant use of carbonic anhydrase inhibitors (e.g., topiramate) and metformin may increase the risk of lactic acidosis. Consider more frequent monitoring.
  • Drugs that reduce metformin clearance such as ranolazine, vandetanib, dolutegravir, or cimetidine may increase the accumulation of metformin and increase the risk of lactic acidosis. Consider the benefits and risks of concomitant use.
  • Alcohol: Alcohol is known to potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake while taking TRIJARDY XR.

TRADJENTA and TRIJARDY XR:

  • Inducers of P-glycoprotein or CYP3A4 Enzymes: The efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Alternative treatments should be used.

USE IN SPECIAL POPULATIONS

Pregnancy: JARDIANCE and TRIJARDY XR are not recommended during the second and third trimesters. With TRIJARDY XR, discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin may result in ovulation in some anovulatory women.

Lactation: JARDIANCE or TRIJARDY XR are not recommended while breastfeeding.

Geriatric Use: With JARDIANCE or TRIJARDY XR, empagliflozin is expected to have diminished efficacy in elderly patients with renal impairment. For TRIJARDY XR, assess renal function more frequently in elderly patients, and dose selection should be cautious, starting at the lowest dose. The incidence of volume depletion-related adverse reactions and urinary tract infections increased in patients ≥75 years treated with empagliflozin.

CL-JAR-100089 08.18.2021

Please see TRIJARDY XR Prescribing Information, including Boxed Warning and Medication Guide.

Please see JARDIANCE Prescribing Information, including Medication Guide.

Please see TRADJENTA Prescribing Information, including Medication Guide.


*3-in-1 pill is a fixed-dose combination treatment
†TRIJARDY XR Savings Card Terms & Conditions apply. Medicare/Medicaid/cash-paying patients excluded from Savings Card enrollment.